US EditionPublished • loading... • Updated
Nanyang Biologics To Go Public in $1.5B SPAC Deal - USA Herald
Summary by USA Herald
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Nanyang Biologics To Go Public in $1.5B SPAC Deal - USA Herald
Singapore-based Nanyang Biologics Pte. Ltd. revealed Thursday it will go public in the U.S. via a merger with special purpose acquisition company RF Acquisition Corp. II, valuing the AI-driven biotech at $1.5 billion before the transaction. The announcement marks a high-stakes entry into Wall Street for the company, which positions itself as a frontrunner in artificial intelligence-powered drug discovery. Nanyang says its crown jewel is “one of …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
